

Arthritis Monoclonal Antibodies Market Analysis With Opportunity Segments For 2024-2033

The Business Research Company's Arthritis Monoclonal Antibodies Global Market Report 2024– Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, August 7, 2024 /EINPresswire.com/ --The arthritis monoclonal antibodies market has experienced robust growth in recent years, expanding from \$58.09 billion in 2023 to \$62.29 billion in 2024



at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"
The Business Research
company

Strong Future Growth Anticipated

The arthritis monoclonal antibodies market is projected to continue its strong growth, reaching \$83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient

preference, and increased healthcare spending.

Explore Comprehensive Insights Into The Global Arthritis Monoclonal Antibodies Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample_request?id=3449&type=smp

Growth Driver Of The Arthritis Monoclonal Antibodies Market

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million

individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis.

Explore The Report Store To Make A Direct Purchase Of The Report:

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Major Players And Market Trends

Key players in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc.

Major companies operating in the arthritis monoclonal antibody market are launching new biosimilar versions such as the Hulio to provide affordable treatment. Hulio is a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug, Humira.

Segments:

- 1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
- 2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
- 3) By End-Use: Hospitals, Research Institutes, Other End-Users

Geographical Insights: North America Leading The Market

North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the <u>arthritis monoclonal antibodies market report</u> are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Arthritis Monoclonal Antibodies Market Definition

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biological medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. To prevent the body from rejecting the new organ after surgery, they reduce the body's defense mechanism.

Arthritis Monoclonal Antibodies Global Market Report 2024 from The Business Research Company covers the following information:

- •Market size data for the forecast period: Historical and Future
- •Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- •Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Arthritis Monoclonal Antibodies Global Market Report 2024 by The Business Research

Company is the most comprehensive report that provides insights on <u>arthritis monoclonal</u> <u>antibodies market size</u>, arthritis monoclonal antibodies market drivers and trends, arthritis monoclonal antibodies market major players, arthritis monoclonal antibodies competitors' revenues, arthritis monoclonal antibodies market positioning, and arthritis monoclonal antibodies market growth across geographies. The arthritis monoclonal antibodies market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Orthobiologics Devices And Equipment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Microbiome Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/microbiomes-global-market-report

Psoriatic Arthritis Treatment Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook

X

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/733605598
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.